The in-vitro activity of two new quinolones: rufloxacin and MF 961
about
Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitisAbsence of effect of rufloxacin on theophylline pharmacokinetics in steady state.Penetration of rufloxacin into the cerebrospinal fluid in patients with inflamed and uninflamed meninges.Biliary excretion of rufloxacin in humans.Pharmacokinetics of rufloxacin in patients with impaired renal function.Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. French Multicenter Urinary Tract Infection-Rufloxacin GroupEx vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.Suspicion of quinolone active metabolite following discrepancy between predicted and experimental urine bactericidal activities.In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.Topical ocular delivery of fluoroquinolones.A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis.A review of the microbiology of amoxycillin/clavulanic acid over the 15 year period 1978-1993.
P2860
Q24670926-375B2FA6-3B23-4CFC-ADC3-FC4E06FE096DQ33696922-DC6452A0-5D4C-4F07-822A-08EE3C04A339Q33978448-DE67ECA9-FAF8-4B5F-AB49-5B164780DA94Q34727021-C6B61E43-00D7-4C5E-BBA1-82FFE340B4C1Q34729777-7D405CB2-2ADD-4928-9245-CC348197955DQ35111149-A2148A3B-311E-49AA-9871-44EA8F21FC93Q35121357-7C28DCDE-3BE6-4236-9841-F054242E6F69Q35122444-9FA70194-1A61-4A47-85F1-EA1E498050E9Q35135686-CDD8388C-2C94-42F7-9C4D-E0F8870FD976Q35822578-6B9DE530-6419-4593-A6A5-AD7D8D07381DQ38082538-E97381A8-4616-4589-9EAE-0CDF041C1D27Q39955572-FD8B7F65-BC2C-4AA8-B474-EB0EF3DF8853Q40596683-6C4A0A01-0D29-4044-972B-5D31A5D400BD
P2860
The in-vitro activity of two new quinolones: rufloxacin and MF 961
description
1992 nî lūn-bûn
@nan
1992 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
The in-vitro activity of two new quinolones: rufloxacin and MF 961
@ast
The in-vitro activity of two new quinolones: rufloxacin and MF 961
@en
The in-vitro activity of two new quinolones: rufloxacin and MF 961
@nl
type
label
The in-vitro activity of two new quinolones: rufloxacin and MF 961
@ast
The in-vitro activity of two new quinolones: rufloxacin and MF 961
@en
The in-vitro activity of two new quinolones: rufloxacin and MF 961
@nl
prefLabel
The in-vitro activity of two new quinolones: rufloxacin and MF 961
@ast
The in-vitro activity of two new quinolones: rufloxacin and MF 961
@en
The in-vitro activity of two new quinolones: rufloxacin and MF 961
@nl
P2093
P356
P1476
The in-vitro activity of two new quinolones: rufloxacin and MF 961
@en
P2093
J M Andrews
M Wolstenholme
R Matthews
P304
P356
10.1093/JAC/29.6.649
P407
P577
1992-06-01T00:00:00Z